Article
Pharmacology & Pharmacy
Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
Summary: This study compared the relative survival rate of gefitinib, erlotinib, and afatinib in EGFR-mutated advanced lung adenocarcinoma patients in Taiwan. Afatinib showed better overall survival and time to treatment failure outcomes compared to gefitinib and erlotinib, especially in patients with initial brain metastases.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Emily K. Kleczko, Anh T. Le, Trista K. Hinz, Teresa T. Nguyen, Andre Navarro, Cheng-Jun Hu, Ana M. Selman, Eric T. Clambey, Daniel T. Merrick, Sizhao Lu, Mary Weiser -Evans, Raphael A. Nemenoff, Lynn E. Heasley
Summary: EGFR mutant lung cancer is highly responsive to TKI treatment, but eventually develops resistance. This study showed that TKI treatment increased T cell content and decreased neutrophil content in tumors, highlighting the importance of adaptive immunity in the therapeutic control of EGFR mutant lung cancer.
Article
Oncology
Natalie Vokes, Emily Chambers, Tom Nguyen, Alexis Coolidge, Christine A. Lydon, Xiuning Le, Lynette Sholl, John Heymach, Mizuki Nishino, Eliezer M. Van Allen, Pasi A. Janne
Summary: This retrospective study analyzed the efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC and its association with genomic alterations. The study found that TP53 alterations were associated with decreased treatment response and faster acquisition of resistance mutations. TP53-mutated tumors had higher mutational burdens and increased mutagenesis with exposure to therapy and tobacco.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Anastasios Gkountakos, Giovanni Centonze, Emanuele Vita, Lorenzo Belluomini, Michele Milella, Emilio Bria, Massimo Milione, Aldo Scarpa, Michele Simbolo
Summary: The use of EGFR tyrosine kinase inhibitors has significantly improved the management of lung adenocarcinoma, but long-term clinical benefit is compromised by multiple resistance mechanisms, including metabolic remodeling. Metabolic pathways and metabolites have been implicated in resistance to EGFR TKIs and they may also serve as predictive biomarkers. Additionally, targeting nutrient dependencies may offer a potential strategy to counteract resistance.
Article
Oncology
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Gee-Chen Chang
Summary: This study aimed to investigate the efficacy of different EGFR-TKIs plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. The results showed that both erlotinib plus bevacizumab and afatinib plus bevacizumab as first-line treatment provided solid clinical efficacy in advanced EGFR-mutant lung adenocarcinoma patients.
CANCER RESEARCH AND TREATMENT
(2022)
Review
Oncology
Yonghui Wu, Kai Zhang, Jiexia Guan, Weibin Wu, Jian Zhang, Huiguo Chen
Summary: Concurrent mutations of EGFR and PIK3CA in non-small cell lung cancer are rare and may complicate treatment. This case report highlights the challenges in managing such cases, as EGFR and PIK3CA concurrent mutations do not respond well to EGFR-TKI treatment. Combination chemotherapy with a TKI may be more effective in this scenario.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Weili Min, Chenyang He, Shuqun Zhang, Yang Zhao
Summary: c-Src activation facilitates metastasis in lung adenocarcinoma through a specific mechanism; although c-Src is not involved in EGFR-related signaling, dasatinib can enhance the anti-tumor activity of TKIs; dasatinib-induced c-Src inactivation sensitizes EGFR-mutant lung adenocarcinoma to TKIs.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang
Summary: This study analyzed the outcomes of advanced EGFR-mutated non-small cell lung cancer patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs. The majority of resistance to first-line therapy was associated with the T790M mutation. Sequential osimertinib treatment in patients with positive secondary T790M mutation showed better outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Junjie Teng, Kai Zhou, Dongxiao Lv, Changshun Wu, Hong Feng
Summary: Targeted therapy and immunotherapy are important treatment options for advanced non-small cell lung cancer (NSCLC). PTEN mutation may serve as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Tony K. H. Chung, Graeme Doran, Tak-Hong Cheung, So-Fan Yim, Mei-Yung Yu, Michael J. Worley, Kevin M. Elias, Aaron R. Thorner, Chandra Sekhar Pedamallu, Akinyemi I. Ojesina, Kei-Man Lau, Matthew D. Ducar, Raymond R. Y. Wong, Vivian W. Wang, Anwesha Nag, Bruce M. Wollison, Audrey Dalgarno, Jacqueline H. S. Lee, Suet-Ying Yeung, Lo Wong, Neil S. Horowitz, Michelle R. Davis, Shuk-On A. Leung, Yi Mu, Samuel C. Mok, Paul K. S. Chan, Michael S. Lawrence, Christopher P. Crum, Rossa W. K. Chiu, Ross S. Berkowitz, Yick-Fu Wong
Summary: In this study, PIK3CA mutations were found to be significantly associated with survival outcomes in cervical adenocarcinoma patients, highlighting the potential for personalized treatment and liquid biopsies in managing this specific type of women's cancer.
Article
Biochemistry & Molecular Biology
Milena Casula, Marina Pisano, Panagiotis Paliogiannis, Maria Colombino, Maria Cristina Sini, Angelo Zinellu, Davide Santeufemia, Antonella Manca, Stefania Casula, Silvia Tore, Renato Lobrano, Antonio Cossu, Giuseppe Palmieri
Summary: Oncogenic mutations in the EGFR gene are targets of tyrosine kinase inhibitors in lung adenocarcinoma patients. Liquid biopsy of ctDNA is increasingly used to detect EGFR mutations. This study compared three different techniques and found that real-time PCR-based methods showed equivalent detection ability to the NGS assay for circulating EGFR mutations, but the NGS assay had a poor ability to detect T790M.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe, Tatsuro Fukuhara, Makoto Maemondo
Summary: EGFR-mutated NSCLC patients with L858R mutation are more likely to respond well to ICI treatment. The occurrence of T790M resistance mutation before ICI treatment did not differ significantly between different response groups. Patients with shorter duration of EGFR-TKI pretreatment are more likely to respond well to ICI treatment.
Article
Oncology
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu
Summary: This retrospective analysis compared the efficacy of afatinib combined with bevacizumab to erlotinib combined with bevacizumab in the first-line treatment of EGFR-mutated NSCLC, showing no significant difference in objective response rate and disease control rate between the two combination therapies, with diarrhea being more common in the afatinib group.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Xiaotong Qiu, Yong Wang, Fen Liu, Lihong Peng, Chen Fang, Xiaoyin Qian, Xinwei Zhang, Qian Wang, Zhehao Xiao, Renfang Chen, Shangkun Yuan, Yong Li
Summary: Studies have shown that non-small cell lung cancer patients with EGFR mutations, but with concurrent PIK3CA mutations, treated with EGFR-TKIs have a shorter time to progression and lower overall survival rates.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Cell Biology
Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Tohru Ohmori, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryo Manabe, Yuki Hasebe, Hironori Sagara, Hitoshi Yoshida, Junji Tsurutani
Summary: This study investigated the mechanisms of osimertinib resistance in NSCLC cells and identified diverse resistance mechanisms. The findings provide insights for developing novel therapeutic strategies for NSCLC.
Article
Cardiac & Cardiovascular Systems
Rani Singh, Barbara Vidal, Juan Ascanio, Naresh Singh Redhu, Jorge Ruiz de Somocurcio, Adnan Majid, Paul A. VanderLaan, Sidhu P. Gangadharan
Summary: Significant changes in gene expression are observed in the tracheal walls of patients with tracheobronchomalacia (TBM) and tracheal stenosis (TS) compared with control subjects.
ANNALS OF THORACIC SURGERY
(2022)
Letter
Critical Care Medicine
Sreyankar Nandy, Rebecca A. Raphaely, Ashok Muniappan, Angela Shih, Benjamin W. Roop, Amita Sharma, Colleen M. Keyes, Thomas V. Colby, Hugh G. Auchincloss, Henning A. Gaissert, Michael Lanuti, Christopher R. Morse, Harald C. Ott, John C. Wain, Cameron D. Wright, Maria L. Garcia-Moliner, Maxwell L. Smith, Paul A. VanderLaan, Sarita R. Berigei, Mari Mino-Kenudson, Nora K. Horick, Lloyd L. Liang, Diane L. Davies, Margit V. Szabari, Peter Caravan, Benjamin D. Medoff, Andrew M. Tager, Melissa J. Suter, Lida P. Hariri
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Paul A. VanderLaan
AMERICAN JOURNAL OF ROENTGENOLOGY
(2022)
Editorial Material
Oncology
Liza M. Quintana, Mayra A. Wells, Paul A. VanderLaan, Vanda F. Torous
CANCER CYTOPATHOLOGY
(2022)
Article
Oncology
Elena Vigliar, Pasquale Pisapia, Filippo Dello Iacovo, Eduardo Alcaraz-Mateos, Greta Ali, Syed Z. Ali, Zubair W. Baloch, Claudio Bellevicine, Massimo Bongiovanni, Pavlina Botsun, Dario Bruzzese, Lukas Bubendorf, Reinhard Buttner, Sule Canberk, Arrigo Capitanio, Chiara Casadio, Eugeniu Cazacu, Beatrix Cochand-Priollet, Alessandro D'Amuri, Katelynn Davis, Catarina Eloy, Marianne Engels, Guido Fadda, Gabriella Fontanini, Franco Fulciniti, Paul Hofman, Antonino Iaccarino, Antonio Ieni, Xiaoyin Sara Jiang, Kennichi Kakudo, Izidor Kern, Ivana Kholova, Kathryn M. Linton McDermott, Chinhua Liu, Anandi Lobo, Maria D. Lozano, Umberto Malapelle, Zahra Maleki, Pamela Michelow, Michael W. Mikula, Jamal Musayev, Gonca Ozgun, Meltem Oznur, Francisca Maria Peiro Marques, David Poller, Michal Pyzlak, Betsy Robinson, Esther Diana Rossi, Sinchita Roy-Chowdhuri, Mauro Saieg, Spasenija Savic Prince, Fernando C. Schmitt, Francisco Javier Segui Ivanez, Tajana Stoos-Veic, Oksana Sulaieva, Brenda J. Sweeney, Giovanni Tuccari, Marie-Louise Van Velthuysen, Paul A. VanderLaan, Philippe Vielh, Patrizia Viola, Quirinus J. M. Voorham, Birgit Weynand, Pio Zeppa, William C. Faquin, Martha Bishop Pitman, Giancarlo Troncone
Summary: This study investigated the impact of the COVID-19 pandemic on cytological practices worldwide. The results showed a persistent reduction in cytological specimen volume during the post-lockdown period, but a significant increase in malignancy rates, indicating a gradual return to normalcy.
CANCER CYTOPATHOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Bess M. Flashner, Paul A. VanderLaan, Lina Nurhussien, Mary B. Rice, Robert W. Hallowell
Summary: The frequency of histopathologic findings varies significantly by antibody type in ILD cases with anti-ARS positivity, with NSIP occurring in less than half of the cases.
RESPIRATORY MEDICINE
(2022)
Article
Oncology
Cynthia K. Harris, Caitlin M. Darrell, Paul A. VanderLaan, Yael K. Heher
Summary: Medical errors are a significant source of harm to patients, but pathologists often fail to directly disclose these errors to patients. The barriers to disclosure include a lack of confidence and training, as well as a lack of preexisting relationships between pathologists and patients. Cytopathologists, who regularly interact with patients during fine-needle aspiration procedures, have an advantage in building rapport. Improving the safety culture in pathology requires the development and support of direct error disclosure practices.
CANCER CYTOPATHOLOGY
(2023)
Letter
Respiratory System
Kai Erik Swenson, Paul VanderLaan, Mihir Parikh
JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY
(2022)
Article
Pathology
Fernando C. Schmitt, Lukas Bubendorf, Sule Canberk, Ashish Chandra, Ian A. Cree, Marianne Engels, Kenzo Hiroshima, Deepali Jain, Ivana Kholova, Lester Layfield, Ravi Mehrotra, Claire W. Michael, Robert Osamura, Martha B. Pitman, Sinchita Roy-Chowdhuri, Yukitoshi Satoh, Paul VanderLaan, Maureen F. Zakowski, Andrew S. Field
Summary: The International Academy of Cytology and the International Agency for Research on Cancer have collaborated to develop a WHO Reporting System for Lung Cytopathology. This system defines five categories for reporting lung cytopathology and provides a standardized approach for testing and diagnosing lung diseases worldwide. It aims to improve patient care and raise the profile of cytopathology.
Article
Oncology
Elizabeth A. A. Hall, Pamela Hartzband, Paul A. A. VanderLaan, Michiya Nishino
Summary: This study evaluates the utility of molecular testing and estimates the risk of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and cancer among patients with cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat fine-needle aspiration. The results show that nodules with nondiagnostic cytology on repeat fine-needle aspiration have a low but nonnegligible risk of NIFTP and/or cancer.
CANCER CYTOPATHOLOGY
(2023)
Article
Oncology
William Shaffer, Ikei S. Kobayashi, Daniel Sentana-Lledo, Shriram Sundararaman, Meghan D. Lee, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa
Summary: This study investigates the therapeutic windows and clinical outcomes of EGFR-K745_E746insIPVAIK and other mutations with exon 19 XPVAIK amino-acid insertions, and finds that these mutations are sensitive to clinically available EGFR TKIs and exhibit similar patterns in terms of therapeutic window and clinical prognosis compared to other mutations.
Article
Endocrinology & Metabolism
Syed Z. Ali, Zubair W. Baloch, Beatrix Cochand-Priollet, Fernando C. Schmitt, Philippe Vielh, Paul A. VanderLaan
Summary: Since its first edition in 2010, The Bethesda System for Reporting Thyroid Cytopathology has provided a standardized reporting system for thyroid fine needle aspirations. The third edition offers key updates, including a single name for each diagnostic category, updated risk of malignancy data, and additional discussion on pediatric thyroid disease and molecular testing. The nomenclature has been aligned with the 2022 World Health Organization Classification of Thyroid Neoplasms, and new chapters on molecular testing and clinical perspectives have been added.
Review
Oncology
Daniel Sentana-Lledo, Emmeline Academia, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Paul A. VanderLaan, Daniel B. Costa
Summary: This review provides an overview of EGFR and ERBB2 mutations in NSCLC and focuses on recent clinical approvals. EGFR mutations occur in 15-20% of NSCLCs, with 10% corresponding to kinase domain insertions in exon 20. ERBB2 mutations occur in 1-4% of NSCLCs, mostly consisting of insertions or point mutations. Mobocertinib and amivantamab have been approved for EGFR exon 20 insertion mutated NSCLC, while fam-trastuzumab deruxtecan-nxki has been approved for ERBB2 mutated NSCLC.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Meeting Abstract
Critical Care Medicine
R. J. Kronen, D. R. Ziehr, A. E. D. Kane, P. VanderLaan, C. A. Kholdani, R. Hallowell
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Article
Respiratory System
Ryan Kronen, David R. Ziehr, Ashley E. D. Kane, Paul A. VanderLaan, Cyrus A. Kholdani, Robert W. Hallowell
Summary: We present a case of a 58-year-old man diagnosed with pulmonary amyloidosis and multiple myeloma, who presented with dyspnea, cough, and weight loss. Lung biopsy revealed amyloid deposits in all three lung compartments, each with distinct pathological manifestations. The patient's condition rapidly progressed, leading to respiratory failure and death.
RESPIRATORY MEDICINE CASE REPORTS
(2022)